SynthesisThoracic cancer2023
Serum cross-linked N-telopeptide of type I collagen as a potential diagnostic marker for bone metastasis in lung cancer: An updated meta-analysis.
Synthesis in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Serum cross-linked N-telopeptide of type I collagen as a potential diagnostic marker for bone metastasis in lung cancer: An updated meta-analysis.Thoracic cancer · 2023Pooled it
- Clinical application of urinary NTx in patients with bone metastases from lung cancer.Journal of bone oncology · 2026Article
- Osteocytes in the Metastatic Bone Niche: Mechanistic Pathways and Therapeutic Targets.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
- The Duality of Collagens in Metastases of Solid Tumors.International journal of molecular sciences · 2025Review
- Inside a Metastatic Fracture: Molecular Bases and New Potential Therapeutic Targets.Cancer medicine · 2025Review
- Review
- Differential Protease Specificity by Collagenase as a Novel Approach to Serum Proteomics That Includes Identification of Extracellular Matrix Proteins without Enrichment.Journal of the American Society for Mass Spectrometry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical value of serum type I collagen cross-linked amino terminal peptide (NTx) for the diagnosis of bone metastasis in lung cancer patients by evidence-based medicine.
methodsDiagnostic studies relevant to NTx as a serum marker for the diagnosis of bone metastasis in lung cancer patients included in the China National Knowledge Infrastructure, Wanfang, PubMed, Embase, and VIP database from the establishment of the databases to November 2022 were retrieved. Meta-analysis was conducted with Stata 16.0 software to calculate the combined sensitivity (SEN), specificity (SPN), positive likelihood ratio (+LR), negative likelihood ratio (-LR), diagnostic odds ratio (DOR), and its 95% confidence interval (CI). The total subject working characteristic curve (summary receiver operating characteristic (SROC) curve) was drawn, and the area under the curve was calculated to evaluate its diagnostic value.
resultsA total of 1742 patients with lung cancer were included in 14 articles. Meta-analysis showed heterogeneity among the studies. The results of random-effect model analysis demonstrated that the combined SEN, SPN, +LR, -LR, and DOR were 0.76 (95% CI 0.66-0.83), 0.80 (95% CI 0.74-0.85), 3.80 (95% CI 2.90-4.80), 0.30 (95% CI 0.22-0.42), and 12 (95% CI 8-19), respectively, and the area under SROC was 0.85.
conclusionSerum NTx has a high clinical value in the diagnosis of bone metastasis in lung cancer patients and can be used as an effective complementary means for imaging diagnosis of bone metastasis in lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.